Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, Qinprezo, in multiple indications to improve the lives of people with cancer. Sunesis has completed a Phase III study evaluating Qinprezo for acute myeloid leukemia (AML), and Phase II studies for platinum-resistant ovarian cancer and advanced solid tumors. (NASDAQ:SNSS)
Sunesis Pharma
